Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) closed the day trading at $33.33 down -5.15% from the previous closing price of $35.14. In other words, the price has decreased by -$5.15 from its previous closing price. On the day, 1.1 million shares were traded.
Ratios:
For a better understanding of HRMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.65. For the most recent quarter (mrq), Quick Ratio is recorded 3.63 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.22.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $55.
On December 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $75.H.C. Wainwright initiated its Buy rating on December 17, 2024, with a $75 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 10 ’25 when JEFFREY G DIERKS bought 5,615 shares for $35.98 per share.
JEFFREY G DIERKS bought 9,844 shares of HRMY for $350,083 on May 19 ’25. On May 16 ’25, another insider, JEFFREY G DIERKS, who serves as the Former Officer of the company, bought 2,292 shares for $35.09 each.
Valuation Measures:
As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.71, and their Forward P/E ratio for the next fiscal year is 8.32. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.57 while its Price-to-Book (P/B) ratio in mrq is 2.65.
Stock Price History:
Over the past 52 weeks, HRMY has reached a high of $41.61, while it has fallen to a 52-week low of $26.47. The 50-Day Moving Average of the stock is 3.61%, while the 200-Day Moving Average is calculated to be -3.78%.
Shares Statistics:
A total of 57.39M shares are outstanding, with a floating share count of 43.61M. Insiders hold about 24.06% of the company’s shares, while institutions hold 78.52% stake in the company.
Earnings Estimates
The company has 3.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $1.07, with high estimates of $1.19 and low estimates of $0.9.
Analysts are recommending an EPS of between $4.82 and $3.56 for the fiscal current year, implying an average EPS of $4.18. EPS for the following year is $5.42, with 3.0 analysts recommending between $5.81 and $4.75.
Revenue Estimates
9 analysts predict $204.34M in revenue for the current quarter. It ranges from a high estimate of $209.5M to a low estimate of $197.01M. As of the current estimate, Harmony Biosciences Holdings Inc’s year-ago sales were $172.81MFor the next quarter, 9 analysts are estimating revenue of $217.82M. There is a high estimate of $222.38M for the next quarter, whereas the lowest estimate is $212.05M.
A total of 9 analysts have provided revenue estimates for HRMY’s current fiscal year. The highest revenue estimate was $855.27M, while the lowest revenue estimate was $826.09M, resulting in an average revenue estimate of $841.12M. In the same quarter a year ago, actual revenue was $714.73MBased on 8 analysts’ estimates, the company’s revenue will be $991.43M in the next fiscal year. The high estimate is $1.05B and the low estimate is $933.77M.
